BAM
PRTK

Belpointe Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Belpointe Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,065
Closed -$228K – 502
2017
Q3 		$228K Buy
+9,065
New +$211K 0.05% 377

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Belpointe Asset Management's PRTK Position: Q4 2017 in Review

Belpointe Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017, closing a stake of 9,065 shares — an estimated $228K sold.

Belpointe Asset Management first reported a position in PRTK in Q3 2017 and held it in 1 quarter. The position peaked at $228K in Q3 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Belpointe Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Belpointe Asset Management sold 9,065 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $228K.
  • Belpointe Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • Belpointe Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $228K in Q3 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Belpointe Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.